Evidence map›Paper›PMID 35860359›Full record

ArticleFrontiers in molecular biosciences2022

Innovative Approach for a Classic Target: Fragment Screening on Trypanothione Reductase Reveals New Opportunities for Drug Design.

Annarita Fiorillo, Gianni Colotti, Cécile Exertier, Anastasia Liuzzi, Francesca Seghetti, Alessandra Salerno, Jessica Caciolla, Andrea Ilari

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. High and Selective TrypanocidalMicroorganisms · 2026
    Article
  3. Article
  4. Article
  5. Molecular interaction assaysThe journal of venomous animals and toxins including tropical diseases · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. In Silico Exploration of the Trypanothione Reductase (TryR) ofInternational journal of molecular sciences · 2023
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Annarita FiorilloInstitute of Molecular Biology and Pathology, Italian National Research Council, IBPM-CNR, Rome, Italy.
Gianni ColottiInstitute of Molecular Biology and Pathology, Italian National Research Council, IBPM-CNR, Rome, Italy.
Cécile ExertierInstitute of Molecular Biology and Pathology, Italian National Research Council, IBPM-CNR, Rome, Italy.
Anastasia LiuzziInstitute of Molecular Biology and Pathology, Italian National Research Council, IBPM-CNR, Rome, Italy.
Francesca SeghettiDepartment of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Alessandra SalernoDepartment of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Jessica CaciollaDepartment of Pharmacy and Biotechnology (FaBiT), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Andrea IlariInstitute of Molecular Biology and Pathology, Italian National Research Council, IBPM-CNR, Rome, Italy.
Institute of Molecular Biology and Pathology · ITUniversity of Bologna · ITNational Research Council · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trypanothione reductase (TR) is a key factor in the redox homeostasis of trypanosomatid parasites, critical for survival in the hostile oxidative environment generated by the host to fight infection. TR is considered an attractive target for the development of new trypanocidal agents as it is essential for parasite survival but has no close homolog in humans. However, the high efficiency and turnover of TR challenging targets since only potent inhibitors, with nanomolar IC50, can significantly affect parasite redox state and viability. To aid the design of effective compounds targeting TR, we performed a fragment-based crystal screening at the Diamond Light Source XChem facility using a library optimized for follow-up synthesis steps. The experiment, allowing for testing over 300 compounds, resulted in the identification of 12 new ligands binding five different sites. Interestingly, the screening revealed the existence of an allosteric pocket close to the NADPH binding site, named the "doorstop pocket" since ligands binding at this site interfere with TR activity by hampering the "opening movement" needed to allow cofactor binding. The second remarkable site, known as the Z-site, identified by the screening, is located within the large trypanothione cavity but corresponds to a region not yet exploited for inhibition. The fragments binding to this site are close to each other and have some remarkable features making them ideal for follow-up optimization as a piperazine moiety in three out of five fragments.

Indexed as

fragment screeningprotein crystallographyrational drug discoverytrypanosomatid infectiontrypanothione reductase

Identifiers

PMID35860359
PMCPMC9289546
OpenAlexW4283790023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.